Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial

被引：0
|
作者：
Dinney, Colin P. N. [1 ]
Narayan, Vikram M. [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USA
[2] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA
来源：
JOURNAL OF UROLOGY | 2024年 / 212卷 / 04期
关键词：
D O I：
10.1097/JU.0000000000004128
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
    Linscott, Joshua
    Li, Roger
    JOURNAL OF UROLOGY, 2024, 212 (04): : 624 - 625
  • [2] Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
    Narayan, Vikram M.
    Boorjian, Stephen A.
    Alemozaffar, Mehrdad
    Konety, Badrinath R.
    Shore, Neal D.
    Gomella, Leonard G.
    Kamat, Ashish M.
    Bivalacqua, Trinity J.
    Montgomery, Jeffrey S.
    Lerner, Seth P.
    Busby, Joseph E.
    Poch, Michael
    Crispen, Paul L.
    Steinberg, Gary D.
    Schuckman, Anne K.
    Downs, Tracy M.
    Mashni, Joseph
    Lane, Brian R.
    Guzzo, Thomas J.
    Bratslavsky, Gennady
    Karsh, Lawrence I.
    Woods, Michael E.
    Brown, Gordon
    Canter, Daniel
    Luchey, Adam
    Lotan, Yair
    Inman, Brant A.
    Williams, Michael B.
    Cookson, Michael S.
    Chang, Sam S.
    Sankin, Alexander I.
    O'Donnell, Michael A.
    Sawutz, David
    Philipson, Richard
    Parker, Nigel R.
    Yla-Herttuala, Seppo
    Rehm, Dorte
    Jakobsen, Jorn S.
    Juul, Kristian
    Dinney, Colin P. N.
    JOURNAL OF UROLOGY, 2024, 212 (01): : 74 - 86
  • [3] Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
    Meeks, Joshua J.
    JOURNAL OF UROLOGY, 2024, 212 (04): : 623 - 624
  • [4] Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial
    Boorjian, S. A.
    Narayan, V. M.
    Konety, B. R.
    Master, V. A.
    Shore, N. D.
    Kamat, A. M.
    Bivalacqua, T. J.
    Kates, M. R.
    Montgomery, J. S.
    Crispen, P. L.
    Steinberg, G. D.
    Agarwal, P. K.
    Schuckman, A. K.
    Karsh, L. I.
    Bjurlin, M. A.
    Brown, G. A.
    Lotan, Y.
    Inman, B. A.
    Williams, M. B.
    Cookson, M. S.
    Chang, S. S.
    Kim, E. H.
    Sankin, A. I.
    Dinney, C.
    EUROPEAN UROLOGY, 2024, 85 : S1492 - S1493
  • [5] EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUERIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL
    Boorjian, Stephen A.
    Narayan, Vikram M.
    Konety, Badrinath R.
    Master, Viraj A.
    Shore, Neal D.
    Kamat, Ashish M.
    Bivalacqua, Trinity J.
    Kates, Max R.
    Montgomery, Jeffrey S.
    Lerner, Seth P.
    Crispen, Paul L.
    Steinberg, Gary D.
    Agarwal, Piyush K.
    Schuckman, Anne K.
    Svatek, Robert S.
    Lane, Brian R.
    Karsh, Lawrence I.
    Bjurlin, Marc A.
    Brown, Gordon A.
    Lotan, Yair
    Inman, Brant A.
    Williams, Michael B.
    Cookson, Michael S.
    Chang, Sam S.
    Kim, Eric H.
    Sankin, Alexander I.
    Rehm, Dorte
    Jakobsen, Jorn S.
    Juul, Kristian
    Dinney, Colin P. N.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E987 - E987
  • [6] EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL
    Stephen, Boorjian A.
    Vikram, Narayan M.
    Viraj, Master A.
    Badrinath, Konety R.
    Neal, Shore D.
    Ashish, Kamat M.
    Colin, Dinney P. N.
    Trinity, Bivalacqua J.
    Max, Kates R.
    Jeffrey, Montgomery S.
    Seth, Lerner P.
    Paul, Crispen L.
    Gary, Steinberg D.
    Piyush, Agarwal K.
    Anne, Schuckman K.
    Robert, Svatek S.
    Brian, Lane R.
    Lawrence, Karsh, I
    Marc, Bjurlin A.
    Gordon, Brown A.
    Yair, Lotan
    Brant, Inman A.
    Michael, Williams B.
    Michael, Cookson S.
    Sam, Chang S.
    Eric, Kim H.
    Alexander, Sankin, I
    Michael, O'Donnell A.
    Jorn, Jakobsen S.
    Kristian, Juul
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S70 - S70
  • [7] Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial
    Boorjian, Stephen A.
    Dinney, Colin P. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy
    Savic, Spasenija
    Zlobec, Inti
    Thalmann, George N.
    Engeler, Daniel
    Schmauss, Martina
    Lehmann, Kurt
    Mattarelli, Gianfranco
    Eichenberger, Tobias
    Dalquen, Peter
    Spieler, Peter
    Schoenegg, Rene
    Gasser, Thomas C.
    Sulser, Tullio
    Forster, Thomas
    Zellweger, Tobias
    Casella, Roberto
    Bubendorf, Lukas
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (12) : 2899 - 2904
  • [9] Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guerin-Naive High-Risk Nonmuscle-Invasive Bladder Cancer REPLY
    不详
    JOURNAL OF UROLOGY, 2022, 208 (03): : 599 - 599
  • [10] Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin: Implications for Clinical Trial Design REPLY
    不详
    JOURNAL OF UROLOGY, 2021, 205 (06): : 1620 - 1621
12345